Old Web
English
Sign In
Acemap
>
authorDetail
>
Viviana Wilches
Viviana Wilches
GlaxoSmithKline
Medicine
human immunodeficiency virus
Pharmacology
Cabotegravir
long acting
3
Papers
9
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression: pOLAR month 12 results.
2021
AIDS
Anthony M. Mills
Gary Richmond
Cheryl L. Newman
Olayemi Osiyemi
Jerry Cade
Cynthia Brinson
Jerome de Vente
David A. Margolis
Kenneth Sutton
Viviana Wilches
Sarah Hatch
Jeremy Roberts
Cynthia McCoig
Cindy Garris
Kati Vandermeulen
William Spreen
Show All
Source
Cite
Save
Citations (0)
116. Antiviral Activity and Safety of Long-acting Cabotegravir (CAB LA) Plus Long-acting Rilpivirine (RPV LA), Administered Every 2 Months (Q2M), in Hiv-positive Subjects: Results from the POLAR Study
2020
Open Forum Infectious Diseases
Anthony Mills
Gary Richmond
Cheryl Newman
Olayemi Osiyemi
Jerry Cade
Cynthia Brinson
Jerome de Vente
Nisha Andany
David A. Margolis
Kenneth Sutton
Viviana Wilches
Jeremy Roberts
Cynthia C McCoig
Kati Vandermeulen
William Spreen
Show All
Source
Cite
Save
Citations (1)
A Phase IIa Study Evaluating Safety, Pharmacokinetics, and Antiviral Activity of GSK2838232, a Novel, Second-generation Maturation Inhibitor, in Participants With Human Immunodeficiency Virus Type 1 Infection
2019
Clinical Infectious Diseases
Edwin DeJesus
Sara Duckworth Harward
Roxanne C. Jewell
Mark A. Johnson
Etienne Dumont
Viviana Wilches
Fiona C. Halliday
Christine L. Talarico
Jerry Jeffrey
Jianjun Gan
Jianfeng Xu
Franco Felizarta
Anita Scribner
Moti Ramgopal
Paul M. Benson
Brian A. Johns
Show All
Source
Cite
Save
Citations (8)
1